Deep Phenotyping of F64L Mutation in a Multicentric Cohort of Patisiran‐Treated Hereditary Transthyretin Amyloidosis Patients (Patisiranitaly)

Read full text
Authors: Marco Ceccanti, Pietro Guaraldi, Angela Romano, Giovanni Antonini, Alessandro Barilaro, Chiara Briani, Marco Burattini, Micol Gianoli, Giulia Carlini, Vittoria Cianci, Marco Currò Dossi, Daniela Di Lisi
+42 more Antonio Di Muzio, Adele Ratti, Massimiliano Filosto, Sabrina Gasverde, Chiara Gemelli, Luca Gentile, Mariangela Goglia, Luca Leonardi, Simone Longhi, Antonio Lotti, Fiore Manganelli, Anna Mazzeo, Sofia Maria Augello, Giammarco Milella, Giuseppina Novo, Davide Pareyson, Silvia Fenu, Giovanni Palumbo, Cristina Petrelli, Loris Poli, Luca Pradotto, Massimo Russo, Alessandro Salvalaggio, Maria Ausilia Sciarrone, Luigi Sellitti, Matteo Tagliapietra, Stefano Tozza, Mariagiovanna Castiglia, Mara Turri, Lorenzo Verriello, Cristina Chimenti, Francesca Vitali, Filippo Brighina, Nicasio Rini, Maurizio Inghilleri, Roberto D’Angelo, Domenico Abelardo, Chiara Cambieri, Laura Libonati, Federica Moret, Marco Luigetti, Vincenzo Di Stefano
Cited by: 1
References: 29

Abstract

BACKGROUND: The F64L variant is among the most frequent TTR mutations in Italy, typically associated with a predominantly neurologic phenotype and limited cardiac involvement. METHODS: Data from 181 ATTRv patients in the multicenter Patisiranitaly database treated with Patisiran since 2020 were analyzed. Neurologic impairment scores, Norfolk QoL-DN, and cardiac parameters were compared between F64L (n = 56), V30M (n = 37), and non-F64L (n = 125) patients at baseline and during follow-up. Cluster analysis was applied to identify patient subgroups based on these variables. RESULTS: F64L represented 30.9% of the cohort. Compared to non-F64L patients, F64L patients had a higher prevalence of neurologic onset and neurologic phenotype, a thinner interventricular septum, and lower NT-proBNP levels. Cluster analysis segregated patients into two distinct groups, predominantly reflecting F64L vs. non-F64L status and corresponding neurologic severity. F64L patients showed milder cardiac involvement compared to V30M patients. Longitudinal repeated-measures ANOVA showed stable clinical and instrumental measures. CONCLUSIONS: F64L is characterized by predominant neurologic involvement and milder cardiac involvement in this Patisiran-treated cohort. Mutation-specific diagnostic and follow-up strategies are essential to capture its natural history and treatment response.

Fields of Study & Subjects

Amyloidosis: Diagnosis Treatment Outcomes Parathyroid Disorders and Treatments Thyroid Cancer Diagnosis and Treatment

Publication details

Journal / source
European Journal of Neurology
Publisher
Wiley
Volume
33
Issue
6
Pages
e70657–e70657
Publication date
1 June 2026
Language
EN